Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer

Figures & data

Table 1 Baseline Clinical, Treatment, and Response Factors of 106 Patients with Stage III NSCLC

N=106	N = 106	%
T stage
T0	2	1.9
T1	14	13
T2	21	20
T3	32	30
T4	37	35
N Stage
N0	8	7.5
N1	8	7.5
N2	63	59.4
N3	27	25.5
Stage (7th edition)
IIIA	62	58.5
IIIB	44	41.5
Median age (range)	62 (47–85)
<50	8	8
50–60	36	34
60–70	34	32
70–80	23	22
80+	5	5
Sex
Male	47	44
Female	59	56
Smoking Status
Current	67	63.2
Former (Quit 1–15 years ago)	14	13.2
Former (Quit >15 years ago)	21	19.8
Never	4	3.8
Histology
Adenocarcinoma	44	41.5
Squamous	53	50.0
Other/Poorly Diff	9	8.5
Prescription Dose
Median Prescription (Gy)	60 (21% SIB)
Median DPF (Gy)	2
Concurrent Chemotherapy
Platinum/taxane	96	90.5
Platinum/etopiside	4	3.7
Platinum/gemcitabine	3	2.8
Platinum/pemetrexed	3	2.8
Consolidation/Maintenance
No	34	32
Yes - Cytotoxic	64	60.3
Yes - Durvalumab	8	7.5
Tumor Volumetrics
25th-50th-75th Initial GTV (cc)	59–110-226 cc
25th-50th-75th % Response	61–74-85%

Figure 1 Absolute Lymphocyte Count (x10³/µL) for each patient during and following completion of chemoradiation.

Table 2 Statistical Significance of Kaplan-Meier Estimates for OS and PFS Based on Baseline Absolute Lymphocyte Count (ALC), Baseline SII, and Recovery ALC, Dichotomized by Median Split and Compared with Wilcoxon Tests

		Adenocarcinoma	Squamous	Entire Cohort
Baseline ALC	OS	p=0.07	p=0.003	p=0.001
	PFS	p=0.58	p=0.05	p=0.09
Baseline SII	OS	p=0.52	p=0.006	p=0.001
	PFS	p=0.58	p=0.54	p=0.02
Recovery ALC	OS	p=0.07	p=0.47	p=0.09
	PFS	p=0.39	p=0.17	p=0.01

Figure 2 Estimates for OS and PFS based on baseline absolute lymphocyte count (ALC), baseline SII, and recovery ALC, dichotomized by median split.